좌골신경통 시장 규모, 점유율, 성장 분석 : 질환 유형별, 약물 종류별, 투여 경로별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Sciatica Market Size, Share, Growth Analysis, By Disease Type, By Drug Class, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032
좌골신경통 세계 시장 규모는 2023년 81억 8,000만 달러로 평가되며, 2024년 86억 5,000만 달러에서 2032년 134억 7,000만 달러로 성장할 것으로 예상되며, 예측 기간(2025-2032년) 동안 연평균 5.7%의 CAGR로 성장할 것으로 예상됩니다.
좌골신경통 세계 시장은 좌식 생활습관, 인구 고령화, 척추 질환의 급증과 관련된 좌골신경통 환자 증가가 주요 요인으로 작용하여 향후 몇 년간 큰 폭의 성장이 예상됩니다. 진단 기술 및 치료 방법의 혁신으로 진단의 정확성과 관리 효과가 향상되고 있습니다. 또한, 조기 개입과 재활의 필요성에 대한 인식이 높아지면서 시장 확대가 가속화되고 있습니다. 그러나 고가의 치료비, 일부 지역에서는 고급 의료 시스템에 대한 접근성 제한, 수술에 따른 위험성 등의 문제도 여전히 남아 있습니다. 이러한 장애물에도 불구하고 최소침습적 기술로의 전환, 새로운 치료제의 도입, 개인화된 치료 솔루션에 대한 의욕이 높아지면서 세계 좌골신경통 시장이 활성화될 것으로 예상됩니다.
목차
소개
조사 방법
- 정보 조달
- 2차 데이터와 1차 데이터 방법
- 시장 규모 예측
- 시장 가정과 제한
주요 요약
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porters 분석
주요 시장 인사이트
- 핵심성공요인
- 경쟁 정도
- 주요 투자 기회
- 시장 생태계
- 시장 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
- 규제 상황
- 기술 평가
- 특허 분석
좌골신경통 시장 규모 : 질환 유형별
- 시장 개요
- 급성 좌골신경통
- 만성 좌골신경통
- 기타
좌골신경통 시장 규모 : 약물 종류별
- 시장 개요
- 비스테로이드성 항염증제
- 경구 스테로이드
- 항경련제
- 삼환계 항우울제
- 오피오이드 진통제
- 기타
좌골신경통 시장 규모 : 투여 경로별
좌골신경통 시장 규모 : 유통 채널별
좌골신경통 시장 규모
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5개사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채용한 전략
- 시장의 최근 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업 개요
- 기업 개요
- 제품 포트폴리오 분석
- 부문별 점유율 분석
- 매출 전년비 비교(2022-2024년)
주요 기업 개요
- Medtronic plc(Ireland)
- Johnson & Johnson(USA)
- Zimmer Biomet Holdings, Inc.(USA)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi S.A.(France)
- Novartis International AG(Switzerland)
- Bristol-Myers Squibb Company(USA)
- Merck & Co., Inc.(USA)
- Zynex Inc.(USA)
- Sorrento Therapeutics, Inc(USA)
- Hikma Pharmaceuticals PLC(UK)
- Viatris Inc.(USA)
- Boston Scientific Corporation(USA)
- Abbott Laboratories(USA)
- Stryker Corporation(USA)
- GlaxoSmithKline plc(UK)
- AstraZeneca plc(UK)
- Eli Lilly and Company(USA)
- Bristol-Myers Squibb Company(USA)
결론과 추천사항
KSM
Global Sciatica Market size was valued at USD 8.18 billion in 2023 and is poised to grow from USD 8.65 billion in 2024 to USD 13.47 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).
The global sciatica market is poised for substantial growth in the upcoming years, primarily due to a rise in sciatica cases linked to sedentary lifestyles, an aging demographic, and a surge in spinal disorders. Innovations in diagnostic technologies and treatment options are enhancing diagnosis accuracy and management effectiveness. Furthermore, heightened awareness of the need for early intervention and rehabilitation is propelling market expansion. However, challenges persist, including high treatment costs, restricted access to advanced healthcare systems in some areas, and risks associated with surgical procedures. Despite these hurdles, the shift toward minimally invasive techniques, the introduction of new therapeutics, and a growing appetite for personalized treatment solutions are anticipated to invigorate the global sciatica market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sciatica market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Sciatica Market Segmental Analysis
Global Sciatica Market is segmented by Disease Type, Drug Class, Route of Administration, Distribution Channel and region. Based on Disease Type, the market is segmented into Acute Sciatica, Chronic Sciatica and Others. Based on Drug Class, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Oral Steroids, Anticonvulsant Agents, Tricyclic Antidepressants, Opioid Analgesics and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Sciatica Market
A significant factor propelling the global sciatica market is the widespread lack of awareness and subsequent underdiagnosis of the condition. Contributing elements include sedentary lifestyles, poor posture, rising obesity rates, and an aging demographic, all of which have led to an increased prevalence of sciatica cases. As awareness grows and more individuals seek proper diagnosis and treatment, there is a heightened demand for effective diagnostic methods, therapeutic interventions, and pain management options. This growing need plays a crucial role in driving the overall expansion of the market and underscores the importance of addressing this overlooked health issue.
Restraints in the Global Sciatica Market
One significant challenge facing the global sciatica market is the prevalent lack of awareness and underdiagnosis associated with the condition. Many individuals experiencing sciatica symptoms are often unaware of their significance, which results in delayed medical intervention and treatment. Additionally, restricted access to healthcare services, particularly in rural regions, exacerbates the issue, restricting timely diagnosis and effective management of sciatica. Enhancing public knowledge about sciatica and improving healthcare infrastructure is crucial to alleviating this restraint. By fostering greater awareness and accessibility, the market can better serve individuals in need and contribute to improved health outcomes for sciatica patients.
Market Trends of the Global Sciatica Market
A prominent trend in the global sciatica market is the rising preference for minimally invasive procedures to address sciatic pain. Treatments such as endoscopic discectomy and percutaneous decompression are increasingly favored over traditional surgeries due to their numerous advantages, including smaller incisions, decreased tissue damage, and shortened recovery times. This shift is largely driven by patient demand for quicker rehabilitation and better overall outcomes, alongside a notable reduction in the risk of complications often associated with invasive surgeries. Consequently, both healthcare providers and patients are gravitating towards these innovative, less invasive options, significantly propelling growth in the global sciatica market.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Regulatory Landscape
- Technology Assessment
- Patent Analysis
Global Sciatica Market Size by Disease Type & CAGR (2025-2032)
- Market Overview
- Acute Sciatica
- Chronic Sciatica
- Others
Global Sciatica Market Size by Drug Class & CAGR (2025-2032)
- Market Overview
- Nonsteroidal Anti-Inflammatory Drugs
- Oral Steroids
- Anticonvulsant Agents
- Tricyclic Antidepressants
- Opioid Analgesics
- Others
Global Sciatica Market Size by Route of Administration & CAGR (2025-2032)
- Market Overview
- Oral
- Injectable
Global Sciatica Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Sciatica Market Size & CAGR (2025-2032)
- North America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
- Europe (Disease Type, Drug Class, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Disease Type, Drug Class, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
- Middle East & Africa (Disease Type, Drug Class, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zimmer Biomet Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zynex Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sorrento Therapeutics, Inc (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boston Scientific Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stryker Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
